Neuroinflammation in schizophrenia especially focused on the role of microglia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 42, Issue , 2013, Pages 115-121

  Monji, Akira ^a   Kato, Takahiro A ^b,c   Mizoguchi, Yoshito ^a   Horikawa, Hideki ^b   Seki, Yoshihiro ^b   Kasai, Mina ^b   Yamauchi, Yusuke ^b   Yamada, Shigeto ^a   Kanba, Shigenobu ^b  

^a SAGA UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Antipsychotics; Cytokine; Microglia; Neuroinflammation; Schizophrenia

Indexed keywords

ACETYLSALICYLIC ACID; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; CYCLOOXYGENASE 2 INHIBITOR; FLUPENTIXOL; HALOPERIDOL; INTERLEUKIN 1BETA; INTERLEUKIN 2; LOXAPINE; OLANZAPINE; PLACEBO; RISPERIDONE; SPIPERONE; TRIFLUPERIDOL; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL FUNCTION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG EFFECT; DRUG MECHANISM; HUMAN; MICROGLIA; NEGATIVE SYNDROME; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT; WHITE MATTER LESION;

ANIMALS; ANTIPSYCHOTIC AGENTS; CYTOKINES; ENCEPHALITIS; FREE RADICALS; HUMANS; MICROGLIA; SCHIZOPHRENIA;

EID: 84873524397     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.12.002     Document Type: Article

References (127)

1. Akhondzadeh S., Tabatabaee M., Amini H., Ahmadi Abhari S.A., Abbasi S.H., et al. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo- controlled trial. Schizophr Res 2007, 90:179-185.
2. Amminger G.P., Schafer M.R., Papageorgiou K., Killer C.M., Cotton S.M., Harrigan S.M., et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010, 67:146-154.
3. Arion D., Unger T., Lewis D.A., Levitt P., Mirnics K. Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry 2007, 62:711-721.
4. Ashdown H., Dumont Y., Ng M., Poole S., Boksa P., Luheshi G.N. The role of cytokines in mediating effects of prenatal infection on the fetus: implication for schizophrenia. Mol Psychiatry 2006, 11:47-55.
5. Bayer T.A., Buslei R., Havas L., Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett 1999, 271:126-128.
6. Behrens M.M., Sejnowski T.J. Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex?. Neuropharamacology 2009, 57:193-200.
7. Behrens M.M., Ali S.S., Dao D.N., Lucero J., Shekhtman G., Dugan L.L. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science 2007, 318:1645-1647.
8. Bernstein H.G., Steiner J., Borgerts B. Glial cells in schizophrenia: pathological significance and possible consequences for therapy. Expert Rev Neurother 2009, 9:1059-1071.
9. Bessis A., Bechade C., Bernard D., Roumier A. Microglial control of neuronal death and synaptic properties. Glia 2007, 55:233-238.
10. Bian Q., Kato T., Monji A., Hashioka S., Mizoguchi Y., Horikawa H., et al. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:42-48.
11. Bilbo S.D., Schwarz J.M. Early-life programming of later-life brain and behavior: a critical role for the immune system. Front Behav Neurosci 2009, 3:1-14.
12. Bland S.T., Beckley J.T., Young S., Watkins L.R., Maier S.F., Bilbo S.D. Enduring consequences of early-life infection on glial and neural cell genesis within cognitive regions of the brain. Brain Behav Immun 2010, 24:329-338.
13. Block M.L., Hong J.S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 2005, 76:77-98.
14. Bojarski L., Debowska K., Wojda U. In vitro findings of alterations in intracellular calcium homeostasis in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1367-1374.
15. Brown A.S., Derkits E.J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010, 167:261-280.
16. Buntinx M., Moreels M., Vandenabeele F., Lambrichts I., Raus J., Steels P., et al. Cytokine-induced cell death in human oligodendroglial cell lines: I. Synergistic effects of IFN-gamma and TNF-alpha on apoptosis. J Neurosci Res 2004, 76:834-845.
17. Cacci E., Claasen J.H., Kokaia Z. Microglia-derived tumor necrosis factor-alpha exaggerates death of newborn hippocampal progenitor cells in vitro. J Neurosci Res 2005, 80:789-797.
18. Cammer W., Zhang H. Maturation of oligodendrocytes is more sensitive to TNF-α than is survival of precursors and immature oligodendrocytes. J Neuroimmunol 1999, 97:37-42.
19. Cazzullo C.L., Sacchetti E., Galluzzo A., Panariello A., Colombo F., Zagliani A., et al. Cytokine profiles in drug-naive schizophrenic patients. Schizophr Res 2001, 47:293-298.
20. Chakos M.H., Schobel S.A., Gu H., Gerig G., Bradford D., Charles C., et al. Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. Br J Psychiatry 2005, 186:26-31.
21. Davis K.L., Stewart D.G., Friedman J.I., Buchsbaum M., Harvey P.D., Hof P.R., et al. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 2003, 60:443-456.
22. Devaraj S.M., Dasu M.R., Jialal I. Diabetes is a proinflammatory state: a translational perspective. Expert Rev Endocrinol Metab 2010, 5:19-28.
23. Deverman B.E., Patterson P.H. Cytokines and CNS development. Neuron 2009, 64:61-78.
24. Doorduin J., de Vries E.F., Willemsen A.T., de Groot J.C., Dierckx D.A., Klein H.C. J Nucl Med 2009, 50:1801-1807.
25. Drexhage R.C., Kniff E.M., Padmos R.C., van der Heul-Nieuwenhuijzen L., Beumer W., Versenal M.A., et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother 2010, 10:59-76.
26. Drzyzga L., Obuchowicz E., Marcinowska A., Herman Z.S. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 2006, 20:532-545.
27. Duan X., Chang J.H., Ge S., Faulkner R.L., Kim J.Y., Kitabatake Y., et al. Disrupted-In-Schizophrenia 1 regulates integration of newly generated neurons in the adult brain. Cell 2007, 130(6):1146-1158.
28. Ekdahl C.T., Claasen J.H., Bonde S., Kokaia Z., Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci U S A 2003, 100:13632-13637.
29. Ellman L.M., Susser E.S. The promise of epidemiologic studies: neuroimmune mechanism in the etiology of brain disorders. Neuron 2009, 64:25-27.
30. Farina C., Aloisi F., Meinl E. Astrocytes are active players in cerebral innate immunity. Trends Neurosci 2008, 28:139-145.
31. Feldhaus B., Dietzel I.D., Heumann R., Berger R. Effects of interferon-gamma and tumor necrosis factor-alpha on survival and differentiation of oligodendrocyte progenitors. J Soc Gynecol Investig 2004, 11:89-96.
32. Fellerhoff B., Wank R. Increased prevalence of Chlamydophila DNA in post-mortem brain frontal cortex from patients with schizophrenia. Schizophr Res 2011, 129:191-195.
33. Gao H.M., Zhou H., Zhang F., Wilson B.C., Kam W., Hong J.S. HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci 2011, 31:1081-1092.
34. Girgis R.R., Diwadkar V.A., Nutche J.J., Sweeney J.A., Keshavan M.S., Hardan A.Y. Risperidone in first-episode psychosis: a longitudinal, exploratory voxel-based morphometric study. Schizophr Res 2006, 82:89-94.
35. Glantz L.A., Gilmore J.H., Lieberman J.A., Jarskog L.F. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr Res 2006, 81:47-63.
36. Graeber M.B., Streit W.J. Microglia: biology and pathology. Acta Neuropathol 2010, 119:89-105.
37. Hanisch U.K. Microglia as a source and target of cytokines. Glia 2002, 40:140-155.
38. Hilleke E., Hulshoff P., Kahn R.S. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull 2008, 34:354-366.
39. Himmerich H., Schonherr J., Fulda S., Shedrick A.J., Bauer K., Sack U. Impact of antipsychotics on cytokine production in-vitro. J Psychiatr Res 2011, 45:1358-1365.
40. Ho B.-C., Andreasen N.C., Ziebell S., Pierson R., Magnotta V. Long-term antipsychotic treatment and brain volumes. Arch Gen Psychiatry 2011, 68:128-137.
41. Hou Y., Wu C.F., Yang J.Y., He X., Bi X.L., Yu L., et al. Effects of clozapine, olanzapine and haloperidol on nitric oxide production by lipopolysaccharide-activated N9 cells. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1523-1528.
42. Hu S., Peterson P.K., Chao C.C. Cytokine-mediated neuronal apoptosis. Neurochem Int 1997, 30:427-431.
43. Iosif R.E., Ekdahl C.T., Ahlenius H., Pronk C.J., Bonde S., Kokaia Z., et al. Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J Neurosci 2006, 26:9703-9712.
44. Jarskog L.F., Glantz L.A., Gilmore J.H., Lieberman J.A. Apoptotic mechanisms in the pathophysiology of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:846-858.
45. Jian P., Wang L., Meltzer H., Zhao z Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. Schizophr Res 2009, 122:38-42.
46. Juckel G., Manitz M.P., Brune M., Friebe A., Heneka M.T., Wolf R.J. Microglial activation in a neuroinflammation animal model of schizophrenia- pilot study. Schizophr Res 2011, 131:96-100.
47. Kaneko N., Kudo K., Mabuchi T., Takemoto K., Fujimaki K., Wati H., et al. Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacology 2006, 31:2619-2626.
48. Kato T., Monji A., Hashioka S., Kanba S. Risperidone significantly inhibits interferon-γ-induced microglial activation in vitro. Schizophr Res 2007, 92:108-115.
49. Kato T., Mizoguchi Y., Monji A., Horikawa H., Suzuki S.O., Seki Y., et al. Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca(2+) regulation in vitro. J Neurochem 2008, 106:815-825.
50. Kato T.A., Monji A., Yasukawa K., Mizoguchi Y., Horikawa H., Seki Y., et al. Aripiprazole inhibits superoxide generation from phorbol-myristate-acetate (PMA)-stimulated microglia in vitro: Implication for antioxidative psychotropic actions via microglia. Schizophr Res 2011, 29:172-182.
51. Kelly D.L., Vyas G., Richardson C.M., Koola M., McMahon R.P., Buchanan R.W., et al. Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophr Res 2011, 133:257-258.
52. Kluge M., Schuld A., Schacht A., Himmerich H., Dalal M.A., Wehmeier P.M., et al. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology 2009, 34:118-128.
53. Knight J.G., Menkes D.B., Highton J., Adams D.D. A rational for a trial of immunosuppressive therapy in acute schizophrenia. Mol Psychiatry 2007, 12:424-431.
54. Kodama M., Fujioka T., Duman R.S. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry 2004, 56:570-580.
55. Kowalski J., Labuzek K., Herman Z.S. Flupentixol and trifluperidol reduce secretion of tumor necrosis factor- and nitric oxide by rat microglial cells. Neurochem Int 2003, 43:173-178.
56. Kowalski J., Labuzek K., Herman Z.S. Flupentixol and trifluperidol reduce interleukin-1 beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Pol J Pharmacol 2004, 56:563-570.
57. Kumra S., Ashtari M., Cervellione K.L., Henderson I., Kester H., Roofeh D., et al. White matter abnormalities in early-onset schizophrenia: a voxel-based diffusion tensor imaging study. J Am Acad Child Adolesc Psychiatry 2005, 44:934-941.
58. Laan W., Grobbee D.E., Selten J.-P., Heijnen C.J., Kahn R.S., Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double blind, placebo-controlled trial. J Clin Psychiatry 2010, 71:520-527.
59. Labuzek K., Kowalski J., Gabryel B., Herman Z.S. Chlorpromazine and loxapine reduce interleukin-1beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Eur Neuropsychopharmacol 2005, 15:23-30.
60. Levkovitz Y., Mendlovich S., Riwkes S., Braw Y., Levkovitch-Verbin H., Gal G., et al. A double-blind randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010, 71:138-149.
61. Li J., Baud O., Vartanian T., Volpe J.J., Rosenberg P.A. Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. Proc Natl Acad Sci U S A 2005, 102:9936-9941.
62. Lieberman J.A. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry 1999, 46:729-739.
63. Lieberman J.A., Tollefson G.D., Charles C., Zipursky R., Sharma T., Kahn R.S., et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005, 62:361-370.
64. Lieberman J.A., Javitch J.A., Moore H. Cholinergic agonists as novel targets for schizophrenia: the promise of rational drug development for psychiatry. Am J Psychiatry 2008, 165:931-936.
65. Lin A., Kenis G., Bignotti S., Tura G.J., De Jong R., Bosmans E., et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 1998, 32:9-15.
66. Liu J., Suzuki T., Seki T., Namba T., Tanimura A., Arai H. Effects of repeated phencyclidine administration on adult hippocampal neurogenesis in the rat. Synapse 2006, 60:56-68.
67. Lu X.H., Dwyer D.S. Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via P13K/AKT, ERK, and pertussis toxin-sensitive pathways. J Mol Neurosci 2005, 27:43-64.
68. Lu D.Y., Tsao Y.Y., Leung Y.M., Su K.P. Docosahexaenoic acid suppresses neuroinflammatory response and induces heme oxygenase-1 expression in BV-2 microglia: implications of antidepressant effects for omega-3 fatty acids. Neuropsychopharmacology 2010, 35:2238-2248.
69. Maeda K., Sugino H., Hirose T., Kitagawa H., Nagai K., Mizoguchi H., et al. Clozapine prevents a decrease in neurogenesis in mice repeatedly treated with phencyclidine. J Pharmacol Sci 2007, 103:299-308.
70. Massana G., Salgado-Pineda P., Junque C., Perez M., Baeza I., Pons A., et al. Volume changes in gray matter in first-episode neuroleptic-naive schizophrenic patients treated with risperidone. J Clin Psychopharmacol 2005, 25:111-117.
71. McCullumsmith R.E., Gupta D., Beneyto M., Kreger E., Haroutunian V., Davis K.L., et al. Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia. Schizophr Res 2007, 90:15-27.
72. Medina S., Martinez M., Hernanz A. Antioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor alpha, dopamine and beta-amyloid peptide 1-42. Free Radic Res 2002, 36:1179-1184.
73. Merrill J.E., Ignarro L.J., Sherman M.P., Melinek J., Lane T.E. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immunol 1993, 151:2132-2141.
74. Meyer U. Anti-inflammatory signaling in schizophrenia. Brain Behav Immun 2011, 25:1507-1518.
75. Meyer J.M., Stahl S.M. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2007, 119:4-14.
76. Miller B.J., Buckley P., Seabott W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine altrations in schizophrenia: clinical studies and antipsychotic effects. Biol Psychiatry 2011, 70:663-671.
77. Mittelbronn M., Dietz K., Schluesener H.J., Meyermann R. Local distribution of microglia in the central nervous system differs by up to one order of magnitude. Acta Neuropathol 2001, 100:249-255.
78. Miyaoka T., Yasukawa R., Yasuda H., Hayashida M., Inagaki T., Horiguchi J. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:304-307.
79. Miyaoka T., Yasukawa R., Yasuda H., Hayashida M., Inagaki T., Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: open-label study. Clin Neuropharmacol 2008, 31:287-292.
80. 2+ in rodent microglia. J Immunol 2009, 183:7778-7786.
81. Monje M.L., Toda H., Palmer T.D. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003, 302:1760-1765.
82. Muller N., Riedel M., Schwarz M.J., Engel R.R. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2005, 255:149-151.
83. Muller N., Krause D., Dehning s, Musil R., Schennach-Wolff R., Obermeirer M., et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 2010, 121:118-124.
84. Nakki R., Koistinaho J., Sharp F.R., Sagar S.M. Cerebellar toxicity of phencyclidine. J Neurosci 1995, 15:2097-2108.
85. Nakki R., Nickdenko J., Chang J., Sagar S.M., Sharp F.R. Haloperidol prevents ketamine- and phencyclidine-induced HSP70 protein expression but not microglial activation. Exp Neurol 1996, 137:234-241.
86. Narayan S., Tang B., Head S.R., Gilmarith T.J., Sutcliffe J.G., Dean B., et al. Molecular profiles of schizophrenia in the CNS at different stages of illness. Brain Res 2008, 1239:235-248.
87. Nawa H., Takei N. Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines. Neurosci Res 2006, 56:2-13.
88. Nielsen J., Skandhede S., Correll C.U. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology 2010, 35:1997-2004.
89. Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308:1314-1318.
90. Palluy O., Rigaud M. Nitric oxide induces cultured cortical neuron apoptosis. Neurosci Lett 1996, 208:1-4.
91. Penzes P., Cahill M.E., Jones K.A., VanLeeuwen J.-E., Woolfrey K.M. Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci 2011, 14:285-293.
92. Perez-Neri I., Ramirez-Bermudez J., Montes S., Rios C. Possible mechanisms of neurodegeneration in schizophrenia. Neurochem Res 2006, 31:1279-1294.
93. Pickard B.S., Pieper A.A., Porteous D.J., Blackwood D.H., Muir W.J. The NPAS3 gene-emerging evidence for a role in psychiatric illness. Ann Med 2006, 38:439-448.
94. Pieper A.A., Wu X., Han T.W., Estill S.J., Dang Q., Wu L.C., et al. The neuronal PAS domain protein 3 transcription factor controls FGF-mediated adult hippocampal neurogenesis in mice. Proc Natl Acad Sci U S A 2005, 102:14052-14057.
95. Pocock J.M., Kettenmann H. Neurotransmitter receptors on microglia. Trends Neurosci 2007, 30:527-535.
96. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008, 63:801-808.
97. Powell SB, Sejnowski TJ, Behrens MM. Behavioral and neurochemical consequences of cortical oxidative stress on parvalbumin-interneuron maturation in rodent models of schizophrenia. Neuropharmacology in press.
98. Price G., Cercignani M., Bagary M.S., Barnes T.R., Barker G.J., Joyce E.M., et al. A volumetric MRI and magnetization transfer imaging follow-up study of patients with first-episode schizophrenia. Schizophr Res 2006, 87:100-108.
99. Radewicz K., Garey L.J., Gentleman S.M., Reynolds R. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J Neuropathol Exp Neurol 2000, 59:137-150.
100. Reif A., Fritzen S., Finger M., Strobel A., Lauer M., Schmitt A., et al. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol Psychiatry 2006, 11:514-522.
101. Reimer J., Fink T., Schafer I., Otte C. Successful treatment of psychosis with infliximab in a patient with Crohn's disease. Schizophr Res 2009, 109:194-195.
102. Roberts R.C., Roche J.K., Conley R.R. Synaptic differences in the post-mortem striatum of subjects with schizophrenia: a stereological and ultrastructural analysis. Synapse 2005, 56:185-197.
103. Rothermundt M., Arolt V., Bayer T.A. Review of immunological and immunopathological findings in schizophrenia. Brain Behav Immun 2001, 15:319-339.
104. Salisbury D.F., Kuroki N., Kasai K., Shenton M.E., McCarley R.W. Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch Gen Psychiatry 2007, 64:521-529.
105. Schiavne S., Sorce S., Dubois-Douphin M., Jaquet V., Colaianna M., Zotti M., et al. Involvement of NOX2 in the development of behavioral and pathological alterations in isolated rats. Biol Psychiatry 2009, 66:384-392.
106. Schlegelmilch T., Henke K., Peri F. Microglia in the developing brain: from immunity to behavior. Curr Opin Neurobiol 2011, 21:5-10.
107. Schlosser R.G., Nenadic I., Wagner G., et al. White matter abnormalities and brain activation in schizophrenia: a combined DTI and fMRI study. Schizophr Res 2007, 89:1-11.
108. Schmitt A., Bertsch T., Henning U., Tost H., Klimke A., Henn F.A., et al. Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms. Schizophr Res 2005, 80:305-313.
109. Schneider T.P., Dwork A.J. Searching for neuropathology: gliosis in schizophrenia. Biol Psychiatry 2011, 69:134-139.
110. Schwarz M.J., Muller N., Riedel M., Ackenheil M. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses 2001, 56:483-486.
111. Snico C.R., Portillo F., Gonzalez-Forero D., Moreno-Lopez B. Nitric oxide-directed synaptic remodeling in the adult mammal CNS. J Neurosci 2005, 25:1448-1458.
112. Soderlund J., Schroder j, Nordin C., Samuelsson M., Walter-Jallow L., Karlsson H., et al. Activation in brain interleukin-1beta in schizophrenia. Mol Psychiatry 2009, 14:1069-1071.
113. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., et al. Common variants conferring risk of schizophrenia. Nature 2009, 460:744-748.
114. Steiner J., Mawrin C., Ziegeler A., Bielau H., Ullrich O., Bernstein H.G., et al. Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol (Berl) 2006, 112:305-316.
115. Steiner J., Bielau H., Brisch R., Danos P., Ullrich O., Mawrin C., et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 2008, 42:151-157.
116. Stellwagen D., Malenka R.C. Synaptic scaling mediated by glial TNF-α. Nature 2006, 440:1054-1059.
117. Sugino H., Futamura T., Mitsumoto Y., Maeda K., Marunaka Y. Atypical antipsychotics suppress production of proinflammatory cytokines and upregulate interleukin-10 in lipopolysaccharide-treated mice. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:303-307.
118. Suzuki T., Hide I., Matsubara A., Hama C., Harada K., Miyano K., et al. Microglial a7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role. J Neurosci Res 2006, 83:1461-1470.
119. Takano A., Arakawa R., Ito H., Tateno A., Takahashi H., Matsumoto R., et al. Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. Int J Neuropsychopharmacol 2010, 13:943-950.
120. Uranova N.A., Vostrikov V.M., Orlovskaya D.D., Rachmanova V.I. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res 2004, 67:269-275.
121. Uranova N.A., Vostrikov V.M., Vikhreva O.V., Zimina I.S., Kolomeets N.S., Orlovskaya D.D. The role of oligodendrocyte pathology in schizophrenia. Int J Neuropsychopharmacol 2007, 10(4):1-9.
122. Van Berckel B.N., Bossong M.G., Boellaard R., Kloet R., Schuitemahen A., Caspers E., et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]-PK11195 positron emission tomography. Biol Psychiatry 2008, 64:820-822.
123. Wakade C.G., Mahadik S.P., Waller J.L., Chiu F.C. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res 2002, 69:72-79.
124. Warner-Schmidt J.L., Duman R.S. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 2006, 16:239-249.
125. Weickert C.S., Hyde T.M., Lipska B.K., Herman M.M., Weinberger D.R., Kleinman J.E. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2003, 8:592-610.
126. Zeng L.T., Hwang J., Ock J., Lee M.G., Lee W.H., Suk K. The antipsychotic spiperone attenuates inflammatory response in cultured microglia via the reductinn of proinflammatory cytokine expression and nitric oxide production. J Neurochem 2008, 107:1225-1235.
127. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., Shen Y.C. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry 2004, 65:940-947.